Northern Trust Corp boosted its holdings in SIGA Technologies, Inc. (OTCMKTS:SIGA) by 2.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 601,928 shares of the biotechnology company’s stock after buying an additional 17,020 shares during the quarter. Northern Trust Corp’s holdings in SIGA Technologies were worth $3,419,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Stone Ridge Asset Management LLC grew its position in SIGA Technologies by 39.2% in the second quarter. Stone Ridge Asset Management LLC now owns 38,404 shares of the biotechnology company’s stock worth $218,000 after buying an additional 10,812 shares during the last quarter. AltraVue Capital LLC grew its position in SIGA Technologies by 13.4% during the 2nd quarter. AltraVue Capital LLC now owns 2,269,113 shares of the biotechnology company’s stock worth $12,888,000 after purchasing an additional 268,106 shares in the last quarter. GSA Capital Partners LLP purchased a new position in SIGA Technologies during the 2nd quarter worth approximately $298,000. Aperio Group LLC grew its position in SIGA Technologies by 47.3% during the 2nd quarter. Aperio Group LLC now owns 18,946 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 6,088 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in SIGA Technologies by 46.1% during the 2nd quarter. Acadian Asset Management LLC now owns 186,841 shares of the biotechnology company’s stock worth $1,061,000 after purchasing an additional 58,916 shares in the last quarter. Hedge funds and other institutional investors own 6.66% of the company’s stock.
In other news, Director Paul G. Savas acquired 10,000 shares of the stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $4.95 per share, for a total transaction of $49,500.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.71% of the company’s stock.
SIGA Technologies (OTCMKTS:SIGA) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.05) earnings per share for the quarter. The business had revenue of $3.91 million for the quarter.
About SIGA Technologies
SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).
Recommended Story: Equal Weight Rating
Want to see what other hedge funds are holding SIGA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SIGA Technologies, Inc. (OTCMKTS:SIGA).
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.